A practical Bayesian design to identify the maximum tolerated dose contour for drug combination trials
暂无分享,去创建一个
[1] J O'Quigley,et al. Continual reassessment method: a practical design for phase 1 clinical trials in cancer. , 1990, Biometrics.
[2] Ying Yuan,et al. Robust EM Continual Reassessment Method in Oncology Dose Finding , 2011, Journal of the American Statistical Association.
[3] Ying Yuan,et al. BAYESIAN PHASE I/II ADAPTIVELY RANDOMIZED ONCOLOGY TRIALS WITH COMBINED DRUGS. , 2011, The annals of applied statistics.
[4] Anastasia Ivanova,et al. Two‐Dimensional Dose Finding in Discrete Dose Space , 2005, Biometrics.
[5] Ying Yuan,et al. Bayesian dose finding in oncology for drug combinations by copula regression , 2009 .
[6] Thomas M Braun,et al. A Hierarchical Bayesian Design for Phase I Trials of Novel Combinations of Cancer Therapeutic Agents , 2010, Biometrics.
[7] Ying Yuan,et al. Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials , 2016, Clinical Cancer Research.
[8] Adrian P Mander,et al. A product of independent beta probabilities dose escalation design for dual-agent phase I trials , 2015, Statistics in medicine.
[9] Ying Yuan,et al. BAYESIAN DATA AUGMENTATION DOSE FINDING WITH CONTINUAL REASSESSMENT METHOD AND DELAYED TOXICITY. , 2013, The annals of applied statistics.
[10] Ying Yuan,et al. Bayesian dose finding by jointly modelling toxicity and efficacy as time‐to‐event outcomes , 2009 .
[11] Ying Yuan,et al. Sequential continual reassessment method for two‐dimensional dose finding , 2008, Statistics in medicine.
[12] Shyamal D Peddada,et al. Designs for Single‐ or Multiple‐Agent Phase I Trials , 2004, Biometrics.
[13] John O'Quigley,et al. Continual Reassessment Method for Partial Ordering , 2011, Biometrics.
[14] Ying Yuan,et al. Bayesian optimal interval designs for phase I clinical trials , 2015, Journal of the Royal Statistical Society: Series C (Applied Statistics).
[15] Ying Yuan,et al. A Bayesian dose finding design for oncology clinical trials of combinational biological agents , 2014, Journal of the Royal Statistical Society. Series C, Applied statistics.
[16] Ying Yuan,et al. A Latent Contingency Table Approach to Dose Finding for Combinations of Two Agents , 2009, Biometrics.
[17] Ying Yuan,et al. A Bayesian dose‐finding design for drug combination clinical trials based on the logistic model , 2014, Pharmaceutical statistics.
[18] R. Dykstra,et al. Isotonic Regression in Two Independent Variables , 1984 .
[19] Ying Yuan,et al. A Bayesian dose finding design for clinical trials combining a cytotoxic agent with a molecularly targeted agent , 2015 .
[20] Thomas M Braun,et al. A Generalized Continual Reassessment Method for Two-Agent Phase I Trials , 2013, Statistics in biopharmaceutical research.
[21] Ying Yuan,et al. Using Data Augmentation to Facilitate Conduct of Phase I–II Clinical Trials With Delayed Outcomes , 2014, Journal of the American Statistical Association.
[22] Peter F Thall,et al. Dose‐Finding with Two Agents in Phase I Oncology Trials , 2003, Biometrics.